Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arfolitixorin vs Leucovorin in Advanced Colorectal Cancer
NCT03750786Phase 3Completed
- Sponsor
- Isofol Medical
- Start
- Dec 2018
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, open-label trial of arfolitixorin in metastatic colorectal cancer (mCRC) (2 arms), sponsored by Isofol Medical. Primary endpoint: Overall Response Rate. Started Dec 2018; status: completed.
02
Drugs
arfolitixorin
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03750786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03750786.